Oct. 17 at 4:06 AM
$KLTO I think that Longevity Biotech 2025 is a huge conference with 72 institutions focused on aging attending.
Looks like among publicly traded companies attending to this conference, Eli Lilly and Company, JP Morgan, Regeneron are the only 3 with large market cap. The rest include universities, research centers and startup ventures with technologies well suited for acquisition by large players.
These innovations include blood based aging factors, compounds that improve insulin sensitivity, a genomic modeling platform, projects supported by federal grants, a designation from the FDA for advanced manufacturing technology, therapies that restore natural killer cell function, an AI optimized enzyme platform and programs designed to reverse disease and aging.
The Wall Street Journal is also involved as a media partner. Overall it looks like a major event and it sounds truly fascinating.
